MX2018013969A - Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. - Google Patents
Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.Info
- Publication number
- MX2018013969A MX2018013969A MX2018013969A MX2018013969A MX2018013969A MX 2018013969 A MX2018013969 A MX 2018013969A MX 2018013969 A MX2018013969 A MX 2018013969A MX 2018013969 A MX2018013969 A MX 2018013969A MX 2018013969 A MX2018013969 A MX 2018013969A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- pure
- receptor antagonist
- nmda
- receptor
- Prior art date
Links
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 2
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al antagonista del receptor 5-HT6 puro o la sal o sales farmacéuticamente aceptables del mismo en combinación o como complementario de un antagonista del receptor NMDA y a su uso en el tratamiento de trastornos cognitivos. La invención también se refiere a la composición farmacéutica que contiene dicha combinación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017203 | 2016-05-18 | ||
| PCT/IB2016/054674 WO2017199072A1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013969A true MX2018013969A (es) | 2019-03-21 |
Family
ID=56940099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013969A MX2018013969A (es) | 2016-05-18 | 2016-08-03 | Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11116764B2 (es) |
| EP (1) | EP3458040B1 (es) |
| JP (1) | JP6606298B2 (es) |
| KR (1) | KR102023748B1 (es) |
| CN (1) | CN109069449A (es) |
| AU (1) | AU2016407428B2 (es) |
| BR (1) | BR112018073396A2 (es) |
| CA (1) | CA3023828C (es) |
| DK (1) | DK3458040T3 (es) |
| EA (1) | EA036301B1 (es) |
| HK (1) | HK1258023A1 (es) |
| HR (1) | HRP20210640T1 (es) |
| HU (1) | HUE055083T2 (es) |
| IL (1) | IL262816B (es) |
| MX (1) | MX2018013969A (es) |
| NZ (1) | NZ747778A (es) |
| SG (1) | SG11201809725TA (es) |
| WO (1) | WO2017199072A1 (es) |
| ZA (1) | ZA201807311B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202090127A1 (ru) * | 2017-07-03 | 2020-04-15 | Сувен Лайф Сайенсиз Лимитед | Новые применения чистого антагониста 5-htрецептора |
| WO2021111330A1 (en) * | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Treating behavioral and psychological symptoms in dementia patients |
| KR20220110518A (ko) * | 2019-12-02 | 2022-08-08 | 수벤 라이프 사이언시스 리미티드 | 치매 환자의 행동 및 심리적 증상 치료 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2310243T3 (es) * | 2002-11-28 | 2009-01-01 | Suven Life Sciences Limited | Indoles n-aril-3-sulfonil sustituidos que tienen afinidad por receptores de serotonina, proceso para su preparacion y composicion farmaceutica que los contiene. |
| EP1902733A1 (en) * | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
| US9540321B2 (en) * | 2013-12-02 | 2017-01-10 | Suven Life Sciences Limited | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate |
-
2016
- 2016-08-03 EP EP16766623.9A patent/EP3458040B1/en active Active
- 2016-08-03 US US16/097,458 patent/US11116764B2/en active Active
- 2016-08-03 HU HUE16766623A patent/HUE055083T2/hu unknown
- 2016-08-03 KR KR1020187035901A patent/KR102023748B1/ko active IP Right Grant
- 2016-08-03 DK DK16766623.9T patent/DK3458040T3/da active
- 2016-08-03 MX MX2018013969A patent/MX2018013969A/es unknown
- 2016-08-03 WO PCT/IB2016/054674 patent/WO2017199072A1/en active Search and Examination
- 2016-08-03 EA EA201892583A patent/EA036301B1/ru unknown
- 2016-08-03 CN CN201680085559.6A patent/CN109069449A/zh active Pending
- 2016-08-03 AU AU2016407428A patent/AU2016407428B2/en active Active
- 2016-08-03 JP JP2018559283A patent/JP6606298B2/ja active Active
- 2016-08-03 BR BR112018073396-2A patent/BR112018073396A2/pt not_active Application Discontinuation
- 2016-08-03 SG SG11201809725TA patent/SG11201809725TA/en unknown
- 2016-08-03 CA CA3023828A patent/CA3023828C/en active Active
- 2016-08-03 NZ NZ747778A patent/NZ747778A/en unknown
-
2018
- 2018-10-31 ZA ZA2018/07311A patent/ZA201807311B/en unknown
- 2018-11-06 IL IL262816A patent/IL262816B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100394.1A patent/HK1258023A1/zh unknown
-
2021
- 2021-04-22 HR HRP20210640TT patent/HRP20210640T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201807311B (en) | 2020-01-29 |
| WO2017199072A1 (en) | 2017-11-23 |
| US11116764B2 (en) | 2021-09-14 |
| CA3023828A1 (en) | 2017-11-23 |
| JP2019516696A (ja) | 2019-06-20 |
| AU2016407428A1 (en) | 2018-11-29 |
| KR20180136566A (ko) | 2018-12-24 |
| US20190175586A1 (en) | 2019-06-13 |
| NZ747778A (en) | 2020-03-27 |
| EP3458040B1 (en) | 2021-01-27 |
| HRP20210640T1 (hr) | 2021-06-25 |
| EA201892583A1 (ru) | 2019-04-30 |
| HUE055083T2 (hu) | 2021-10-28 |
| JP6606298B2 (ja) | 2019-11-13 |
| KR102023748B1 (ko) | 2019-09-20 |
| EA036301B1 (ru) | 2020-10-23 |
| EP3458040A1 (en) | 2019-03-27 |
| AU2016407428B2 (en) | 2019-11-21 |
| HK1258023A1 (zh) | 2019-11-01 |
| IL262816B (en) | 2020-05-31 |
| BR112018073396A2 (pt) | 2019-03-19 |
| SG11201809725TA (en) | 2018-12-28 |
| IL262816A (en) | 2018-12-31 |
| CA3023828C (en) | 2019-08-27 |
| CN109069449A (zh) | 2018-12-21 |
| DK3458040T3 (da) | 2021-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
| MX2021002322A (es) | Nuevos metodos. | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| NZ744982A (en) | Therapeutic compounds | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| CY1123013T1 (el) | Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης | |
| MX2018013969A (es) | Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
| SA519410097B1 (ar) | P2x7 مشتقات رباعي هيدروكوينولين كمعارضات مستقبل | |
| MX2018014184A (es) | Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. | |
| JO3367B1 (ar) | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 | |
| PH12017501736A1 (en) | Indole derivatives | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| IT201600122310A1 (it) | Composizione per uso nella terapia di alterazioni dell'intestino | |
| NZ750150A (en) | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors | |
| MX2019001698A (es) | Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de la acetilcolinestearasa y antagonistas del receptor nmda. | |
| EA202090397A1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| WO2016083315A8 (en) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases | |
| MX2017008497A (es) | Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética. | |
| IN2013MU03838A (es) |